Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma

被引：47
|
作者：
Kudo, Masatoshi [1 ]
机构：
[1] Kindai Univ, Fac Med, Dept Gastroenterol & Hepatol, Osaka, Japan
来源：
LIVER CANCER | 2022年 / 11卷 / 05期
关键词：
Atezolizumab plus bevacizumab; Hepatocellular carcinoma; ABC conversion; Curative therapy; Cancer-free status; Drug-free status; POSITRON-EMISSION-TOMOGRAPHY; T-CELL RESPONSES; RADIOFREQUENCY ABLATION; F-18-FDG PET/CT; TUMOR; LENVATINIB; DIFFERENTIATION; IDENTIFICATION; ENHANCEMENT; MULTICENTER;
D O I：
10.1159/000526163
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：399 / 406
页数：8
相关论文
共 50 条
  • [1] Primary analysis of a phase II study of atezolizumab plus bevacizumab for TACE-unsuitable patients with tumor burden beyond up-to-seven criteria in intermediate-stage hepatocellular carcinoma: REPLACEMENT study
    Ueshima, Kazuomi
    Kudo, Masatoshi
    Tsuchiya, Kaoru
    Kato, Naoya
    Yamashita, Tatsuya
    Shimose, Shigeo
    Numata, Kazushi
    Kodama, Yuzo
    Tanaka, Yasuhito
    Kuroda, Hidekatsu
    Itoh, Shinji
    Aikata, Hiroshi
    Hiraoka, Atsushi
    Moriguchi, Michihisa
    Wada, Yoshiyuki
    Nakao, Kazuhiko
    Tateishi, Ryosuke
    Ogasawara, Sadahisa
    Yamamoto, Kouji
    Ikeda, Masafumi
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] Transarterial chemoembolization combined with atezolizumab plus bevacizumab conversion therapy for intermediate-stage hepatocellular carcinoma: a case report and literature review
    Ai, Haidong
    Gong, Ting
    Ma, Yongbiao
    Ma, Guixu
    Ding, Wei
    Ding, Weibao
    Wang, Wenjuan
    Zhao, Xuelin
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [3] Achievement of cancer- and treatment-free status by atezolizumab plus bevacizumab combined with or without curative conversion in patients with transarterial chemoembolization-unsuitable, intermediate-stage hepatocellular carcinoma: A multicenter cohort study.
    Kudo, Masatoshi
    Aoki, Tomoko
    Ueshima, Kazuomi
    Tsuchiya, Kaoru
    Morita, Masahiro
    Hagiwara, Satoru
    Minami, Yasunori
    Ida, Hiroshi
    Nishida, Naoshi
    Ogawa, Chikara
    Tomonari, Tetsu
    Nakamura, Noriaki
    Kuroda, Hidekatsu
    Takebe, Atsushi
    Takeyama, Yoshifumi
    Hidaka, Masaaki
    Eguchi, Susumu
    Chan, Stephen Lam
    Kurosaki, Masayuki
    Izumi, Namiki
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 535 - 535
  • [4] Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate-stage hepatocellular carcinoma
    Tada, Toshifumi
    Kumada, Takashi
    Hiraoka, Atsushi
    Hirooka, Masashi
    Kariyama, Kazuya
    Tani, Joji
    Atsukawa, Masanori
    Takaguchi, Koichi
    Itobayashi, Ei
    Fukunishi, Shinya
    Tsuji, Kunihiko
    Ishikawa, Toru
    Tajiri, Kazuto
    Ochi, Hironori
    Yasuda, Satoshi
    Toyoda, Hidenori
    Ogawa, Chikara
    Nishimura, Takashi
    Hatanaka, Takeshi
    Kakizaki, Satoru
    Shimada, Noritomo
    Kawata, Kazuhito
    Tada, Fujimasa
    Ohama, Hideko
    Nouso, Kazuhiro
    Morishita, Asahiro
    Tsutsui, Akemi
    Nagano, Takuya
    Itokawa, Norio
    Okubo, Tomomi
    Arai, Taeang
    Imai, Michitaka
    Kosaka, Hisashi
    Naganuma, Atsushi
    Matono, Tomomitsu
    Aoki, Tomoko
    Kuroda, Hidekatsu
    Yata, Yutaka
    Koizumi, Yohei
    Nakamura, Shinichiro
    Kaibori, Masaki
    Iijima, Hiroko
    Hiasa, Yoichi
    Kudo, Masatoshi
    LIVER INTERNATIONAL, 2024, 44 (01) : 113 - 124
  • [5] Achievement of Complete Response and Drug-free Status by Atezolizumab Plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-stage Hepatocellular Carcinoma: A Multicenter Proof-of-Concept Study
    Kudo, Masatoshi
    Aoki, Tomoko
    Ueshima, Kazuomi
    Tsuchiya, Kaoru
    Morita, Masahiro
    Chishina, Hirokazu
    Takita, Masahiro
    Hagiwara, Satoru
    Minami, Yasunori
    Ida, Hiroshi
    Nishida, Naoshi
    Ogawa, Chikara
    Tomonari, Tetsu
    Nakamura, Noriaki
    Kuroda, Hidekatsu
    Takebe, Atsushi
    Takeyama, Yoshifumi
    Hidaka, Masaaki
    Eguchi, Susumu
    Chan, Stephen L.
    Kurosaki, Masayuki
    Izumi, Namiki
    LIVER CANCER, 2023, 12 (04) : 321 - 338
  • [6] Proposal of discontinuation criteria of atezolizumab plus bevacizumab after curative conversion therapy for unresectable early-to-intermediate-stage hepatocellular carcinoma: a multicenter proof-of-concept study
    Aoki, Tomoko
    Kudo, Masatoshi
    Nishida, Naoshi
    Ueshima, Kazuomi
    Tsuchiya, Kaoru
    Tada, Toshifumi
    Morita, Masahiro
    Chishina, Hirokazu
    Takita, Masahiro
    Hagiwara, Satoru
    Ida, Hiroshi
    Minami, Yasunori
    Kuroda, Hidekatsu
    Nakamura, Noriaki
    Hiraoka, Atsushi
    Tomonari, Tetsu
    Tani, Joji
    Naganuma, Atsushi
    Kakizaki, Satoru
    Ogawa, Chikara
    Hatanaka, Takeshi
    Ishikawa, Toru
    Kawata, Kazuhito
    Takebe, Atsushi
    Matsumoto, Ippei
    Hidaka, Masaaki
    Kurosaki, Masayuki
    Kumada, Takashi
    Izumi, Namiki
    JOURNAL OF GASTROENTEROLOGY, 2025,
  • [7] Treatment effect of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma aiming at curative conversion therapy
    Tomonari, Tetsu
    Tani, Joji
    Sato, Yasushi
    Tanaka, Hironori
    Taniguchi, Tatsuya
    Kawano, Yutaka
    Masaki, Tsutomu
    Takayama, Tetsuji
    ANNALS OF ONCOLOGY, 2023, 34 : S1399 - S1399
  • [8] A Novel Treatment Strategy for Patients with Intermediate-Stage HCC Who Are Not Suitable for TACE: Upfront Systemic Therapy Followed by Curative Conversion
    Kudo, Masatoshi
    LIVER CANCER, 2021, 10 (06) : 539 - 544
  • [9] Efficacy of Atezolizumab Plus Bevacizumab-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma
    Moriyama, Etsuko
    Shimose, Shigeo
    Niizeki, Takashi
    Iwamoto, Hideki
    Tanaka, Masatoshi
    Shirono, Tomotake
    Noda, Yu
    Nakano, Masahito
    Kuromatsu, Ryoko
    Koga, Hironori
    Kawaguchi, Takumi
    CURRENT ONCOLOGY, 2024, 31 (10) : 5821 - 5831
  • [10] ABC-HCC: A phase IIIb, randomized, multicenter, open-label trial of atezolizumab plus bevacizumab versus transarterial chemoembolization (TACE) in intermediate-stage hepatocellular carcinoma
    Foerster, Friedrich
    Kloeckner, Roman
    Reig, Maria
    Chan, Stephen Lam
    Chung, Jin Wook
    Merle, Philippe
    Park, Joong-Won
    Piscaglia, Fabio
    Vogel, Arndt
    Gaillard, Vincent
    Bruix, Jordi
    Galle, Peter R.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
12345